Tiziana Life Sciences Ltd
TLSA
$2.03
-$0.10-4.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.58M | 11.57M | 10.57M | 9.48M | 8.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.47M | 17.13M | 15.79M | 15.80M | 15.80M |
| Operating Income | -18.47M | -17.13M | -15.79M | -15.80M | -15.80M |
| Income Before Tax | -14.40M | -15.57M | -16.75M | -16.68M | -16.61M |
| Income Tax Expenses | -1.56M | -3.22M | -4.88M | -3.88M | -2.88M |
| Earnings from Continuing Operations | -12.84 | -12.35 | -11.86 | -12.80 | -13.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.84M | -12.35M | -11.86M | -12.80M | -13.73M |
| EBIT | -18.47M | -17.13M | -15.79M | -15.80M | -15.80M |
| EBITDA | -18.46M | -17.12M | -15.78M | -15.79M | -15.79M |
| EPS Basic | -0.11 | -0.11 | -0.11 | -0.12 | -0.13 |
| Normalized Basic EPS | -0.10 | -0.09 | -0.09 | -0.09 | -0.09 |
| EPS Diluted | -0.11 | -0.11 | -0.11 | -0.12 | -0.13 |
| Normalized Diluted EPS | -0.10 | -0.09 | -0.09 | -0.09 | -0.09 |
| Average Basic Shares Outstanding | 454.15M | 440.42M | 426.69M | 419.11M | 411.54M |
| Average Diluted Shares Outstanding | 454.15M | 440.42M | 426.69M | 419.11M | 411.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |